Roivant Sciences LtdROIV

Buy more

Buy more on a dip to our buy price, which is under today's $40.

8 good· Earnings beat
1 to watch· Thinner margin

$40.20−1.65 (−3.94%)

Price at 3:03 PM ET

After hours · opens in 17h 24m

NASDAQ · Healthcare · Large company

Tell me when ROIV moves 5% in a day

The price we'd buy ROIV at comes with a free account

It also has the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.

What would change it

Sources

From the 10-Q for the quarter to Jun 30, reported Aug 6
Yahoo Finance daily closes to Nov 9

Any one could move it to Keep

Next report

below51%
sales growth

Compared with the S&P 500

14 points
worse in one day
30 points
worse in five trading days

+89.9% in a yearsince Nov 10, 2025

Earnings report

Latest results

Reported Monday before the open

EPS: −$0.18; vs −$0.45 expected, beat by 60%
The stock: +4.6%; On Monday, usually 2.7%

Our call is still Buy more after the results.

The news behind our call

written Monday, 5:29 PM ETMonday, 5:29 PM ET · 12 articles · 5 sources

Roivant beat quarterly EPS expectations.
IMVT-1402 targets 85,000 difficult-to-treat rheumatoid arthritis patients.
Healthcare stocks are broadly advancing.

What changed

From Yahoo Finance, Roivant Sciences Ltd via Seeking Alpha, Roivant Sciences Ltd via Yahoo Finance and 1 more

How Trial wins and Drug launch revenue will Impact Roivant Sciences stock
Today
Roivant Sciences Ltd (ROIV) (Q2 2026) earnings call highlights: LISRIA launch Delivers $31 ...
Tuesday
ROIV beat EPS estimates as shares rose 4.58%, but commercial execution remains the key test
Reported EPS was -$0.18 versus estimated EPS of -$0.45, a $0.27 beat and 58.88% positive surprise. Formal forward guidance was not provided in the payload; management’s guidance tone is therefore unknown.
Earnings · Monday
Roivant Sciences (ROIV) Q2 2026 earnings call transcript
Monday
Roivant outlines Investor Day focus as IMVT-1402 targets 85,000 difficult-to-treat RA patients
Monday
Roivant Sciences Ltd. (ROIV) Q2 2026 earnings call transcript
Monday
Roivant Sciences Q2 earnings call highlights
Monday
Roivant Sciences Q2 2027 earnings call transcript
Monday

Overview

In plain numbers

Revenue grew 102% from a year earlier, to $41.1M in the last twelve months.
It loses $31.79 on every revenue dollar at the operating line, down from a loss of $15.17 in FY 2022.
It burned $758.6M of free cash in FY 2026.
It holds $3.8B in cash and investments against $107.2M of debt, which leaves $3.7B of net cash.

Key figures

Revenue (TTM): $41.1M
Revenue growth, 1 year: +102.1%
Net income: −$344M
EPS (diluted): −$0.59
Operating margin: -3179.2%

Return on equity: -8.5%
Return on capital: -110.0%
Debt / equity: 0.02
Current ratio: 16.72
Buyback yield: -2.37%

Key facts

Company value: $29.4B
Today's range: 40.1741.50
Past year's range: 20.1041.81

Yesterday's close: $41.85
Swings vs the market: 1.1×about the same